Allon Therapeutics Inc.
NPCUF
$0.0001
$0.000.00%
| 03/31/2013 | 12/31/2012 | 09/30/2012 | 06/30/2012 | 03/31/2012 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 466.60K | 781.00K | 572.00K | 811.00K | 635.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.04M | 3.14M | 1.87M | 3.04M | 2.77M |
| Operating Income | -1.04M | -3.14M | -1.87M | -3.04M | -2.77M |
| Income Before Tax | -1.06M | -7.11M | -1.86M | -3.21M | -2.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.06M | -7.11M | -1.86M | -3.21M | -2.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.06M | -7.11M | -1.86M | -3.21M | -2.77M |
| EBIT | -1.04M | -3.14M | -1.87M | -3.04M | -2.77M |
| EBITDA | -1.04M | -3.03M | -1.74M | -2.91M | -2.64M |
| EPS Basic | -0.01 | -0.05 | -0.01 | -0.03 | -0.03 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -0.02 | -0.02 |
| EPS Diluted | -0.01 | -0.05 | -0.01 | -0.03 | -0.03 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 141.10M | 140.84M | 140.56M | 115.58M | 100.56M |
| Average Diluted Shares Outstanding | 141.10M | 140.84M | 140.56M | 115.58M | 100.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
